Co-Authors
This is a "connection" page, showing publications co-authored by Richard Silver and Marcy Bolster.
Connection Strength
1.183
-
Assessment and management of scleroderma lung disease. Curr Opin Rheumatol. 1999 Nov; 11(6):508-13.
Score: 0.183
-
Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
Score: 0.153
-
Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1994 Nov; 6(6):642-9.
Score: 0.130
-
Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol. 1993 Feb; 7(1):79-97.
Score: 0.115
-
Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
Score: 0.077
-
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
Score: 0.071
-
Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
Score: 0.066
-
Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
Score: 0.060
-
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
Score: 0.049
-
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
Score: 0.042
-
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
Score: 0.037
-
Cognitive deficits in a murine model of the eosinophilia-myalgia syndrome: a preliminary report. Neurotoxicol Teratol. 1996 Sep-Oct; 18(5):595-601.
Score: 0.037
-
A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome. Proc Assoc Am Physicians. 1996 Jul; 108(4):315-22.
Score: 0.036
-
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
Score: 0.031
-
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
Score: 0.020
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
Score: 0.020
-
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
Score: 0.019
-
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
Score: 0.019
-
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
Score: 0.018